WO2002020049A3 - Eiav chimeric vaccine and diagnostic - Google Patents

Eiav chimeric vaccine and diagnostic

Info

Publication number
WO2002020049A3
WO2002020049A3 PCT/US2001/027599 US0127599W WO0220049A3 WO 2002020049 A3 WO2002020049 A3 WO 2002020049A3 US 0127599 W US0127599 W US 0127599W WO 0220049 A3 WO0220049 A3 WO 0220049A3
Authority
WO
WIPO (PCT)
Prior art keywords
eiav
diagnostic
vaccine
chimeric vaccine
vaccinated
Prior art date
Application number
PCT/US2001/027599
Other languages
French (fr)
Other versions
WO2002020049A2 (en
Inventor
Ronald C Montelaro
Jodi Craigo
Charles Issel
Bridget Puffer
Kristina J Hennessey
Karen K Brown
Original Assignee
Akzo Nobel Nv
Ronald C Montelaro
Jodi Craigo
Charles Issel
Bridget Puffer
Kristina J Hennessey
Karen K Brown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv, Ronald C Montelaro, Jodi Craigo, Charles Issel, Bridget Puffer, Kristina J Hennessey, Karen K Brown filed Critical Akzo Nobel Nv
Priority to AU2001287103A priority Critical patent/AU2001287103B2/en
Priority to EP01966602A priority patent/EP1345622A2/en
Priority to BR0113745-0A priority patent/BR0113745A/en
Priority to AU8710301A priority patent/AU8710301A/en
Priority to JP2002524532A priority patent/JP2004522697A/en
Publication of WO2002020049A2 publication Critical patent/WO2002020049A2/en
Publication of WO2002020049A3 publication Critical patent/WO2002020049A3/en
Priority to AU2007201936A priority patent/AU2007201936A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Disclosed herein is a lentivirus chimera vaccine and diagnostic and methods of making and using the same, which can be used safety and effectively to provide immunity to mammals from infection and/or disease caused by a lentivirus, such as equine infectious anemia virus (EIAV) and which vaccine allows differentiation between vaccinated and non-vaccinated, but exposed mammals particularly horses.
PCT/US2001/027599 2000-09-09 2001-09-06 Eiav chimeric vaccine and diagnostic WO2002020049A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2001287103A AU2001287103B2 (en) 2000-09-09 2001-09-06 EIAV chimeric vaccine and diagnostic
EP01966602A EP1345622A2 (en) 2000-09-09 2001-09-06 Eiav chimeric vaccine and diagnostic
BR0113745-0A BR0113745A (en) 2000-09-09 2001-09-06 Vaccine, diagnostic test and methods for immunizing mammals and preparing a vaccine
AU8710301A AU8710301A (en) 2000-09-09 2001-09-06 Eiav chimeric vaccine and diagnostic
JP2002524532A JP2004522697A (en) 2000-09-09 2001-09-06 EIAV chimeric vaccines and diagnostics
AU2007201936A AU2007201936A1 (en) 2000-09-09 2007-05-01 EIAV Chimeric Vaccine and Diagnostic

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65902900A 2000-09-09 2000-09-09
US09/659,029 2000-09-09

Publications (2)

Publication Number Publication Date
WO2002020049A2 WO2002020049A2 (en) 2002-03-14
WO2002020049A3 true WO2002020049A3 (en) 2003-07-03

Family

ID=24643739

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/027599 WO2002020049A2 (en) 2000-09-09 2001-09-06 Eiav chimeric vaccine and diagnostic

Country Status (5)

Country Link
EP (1) EP1345622A2 (en)
JP (1) JP2004522697A (en)
AU (2) AU8710301A (en)
BR (1) BR0113745A (en)
WO (1) WO2002020049A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005292A1 (en) * 1994-08-15 1996-02-22 Connaught Laboratories Limited Antigenically-marked non-infectious retrovirus-like particles
WO1998039463A2 (en) * 1997-03-06 1998-09-11 Ueberla Klaus Lentivirus based vector and vector system
WO1999032646A1 (en) * 1997-12-22 1999-07-01 Oxford Biomedica (Uk) Limited Equine infectious anaemia virus (eiav) based
WO2000063387A1 (en) * 1999-04-21 2000-10-26 National Center For Aids Prevention And Control The full gene sequence of the donkey leukocyte vaccine strain of the equine infectious anemia virus and their application

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3873690A (en) * 1974-01-23 1975-03-25 Iii James H Rand Equine infectious anemia vaccine
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
AU741747B2 (en) * 1997-05-13 2001-12-06 University Of North Carolina At Chapel Hill, The Lentivirus-based gene transfer vectors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005292A1 (en) * 1994-08-15 1996-02-22 Connaught Laboratories Limited Antigenically-marked non-infectious retrovirus-like particles
WO1998039463A2 (en) * 1997-03-06 1998-09-11 Ueberla Klaus Lentivirus based vector and vector system
WO1999032646A1 (en) * 1997-12-22 1999-07-01 Oxford Biomedica (Uk) Limited Equine infectious anaemia virus (eiav) based
WO2000063387A1 (en) * 1999-04-21 2000-10-26 National Center For Aids Prevention And Control The full gene sequence of the donkey leukocyte vaccine strain of the equine infectious anemia virus and their application
EP1174507A1 (en) * 1999-04-21 2002-01-23 National Center for Aids prevention and control The full gene sequence of the donkey leukocyte vaccine strain of the equine infectious anemia virus and their application

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LU J ET AL: "DIFFERENTIAL TEST ON SERUM ANTIBODY FROM EIA HORSES WITH THAT FROM ATTENUATED EIA VACCINE IMMUNIZED HORSES", SCIENTIA AGRICULTURA SINICA, vol. 22, no. 6, 1989, pages 69 - 75, XP001148407, ISSN: 0578-1752 *
VIGNE R ET AL: "PRECURSOR POLY PEPTIDES TO STRUCTURAL PROTEINS OF VISNA VIRUS", JOURNAL OF VIROLOGY, vol. 42, no. 3, 1982, pages 1046 - 1056, XP008014040, ISSN: 0022-538X *

Also Published As

Publication number Publication date
EP1345622A2 (en) 2003-09-24
AU8710301A (en) 2002-03-22
JP2004522697A (en) 2004-07-29
AU2001287103B2 (en) 2007-02-01
BR0113745A (en) 2004-03-02
WO2002020049A2 (en) 2002-03-14

Similar Documents

Publication Publication Date Title
ZA200701176B (en) Vaccines against aids comprising CMV/R-nucleic acid constructs
ATE451119T1 (en) SUBUNITY VACCINE AGAINST RESPIRATORY SYNZYTIAL VIRUS
WO2007064742A3 (en) Identification of protective antigenic determinants of porcine reproductive and respiratory syndrome virus (prrsv) and uses thereof
EE9900343A (en) Synthetic Polynucleotide, Immune Response Method, Immunogenic Composition, Anti-HIV Immune Response Induction Method, Antigen-Inducing Cell Indication, and Pharmaceutical Composition
EP4219566A3 (en) Recombinant rsv antigens
MX9203458A (en) IMMUNOGENIC SEGMENTS CONTAINING CHEMICAL GLYCOPROTEINS FROM HUMAN RESPIRATORY SYNCITIAL VIRUS GLYCOPROTEINS.
HU9401056D0 (en) Porcine reproductive respiratory syndrome vaccine and diagnostic
WO2003028632A3 (en) Development of a preventive vaccine for filovirus infection in primates
HK1043943A1 (en) Streptococcus pneumoniae proteins and vaccines
AP2002002685A0 (en) Use of flavivirus for the expression of protein epitpoes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents
WO2002036790A3 (en) Influenza virus vector for infection of dendritic cells
WO2002045742A8 (en) Lipoteichoic acid immunogenic compositions and methods of making and using thereof
WO2003059385A3 (en) Hiv vaccine and method of use
EA200700496A1 (en) INACTIVATED POLYOMYELITE VACCINE, RECEIVED FROM STRAIN OF SEIBIN VIRUS OF POLIOMYELITIS
WO2002004002A3 (en) Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals
ATE310008T1 (en) IMMUNOLOGICAL ADJUVANT COMPOUNDS
WO2004100985A3 (en) Materials and methods for immunizing against fiv infection
MXPA03009763A (en) Foot and mouth disease virus vaccine.
WO2001004280A3 (en) Vaccine against lentiviral infections, such as the feline immune deficiency virus of the cat
WO2002020049A3 (en) Eiav chimeric vaccine and diagnostic
DE69738641D1 (en) LIVING VACCINE AGAINST HELIOBACTER PYLORI
WO2001074386A3 (en) Cold-adapted equine influenza viruses
NO20020615D0 (en) Vaccine
CA2457804A1 (en) Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
HUP0204176A2 (en) Recombinant attenuation of prrsv

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001966602

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002524532

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001287103

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001966602

Country of ref document: EP